KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Receivables: 2010-2025

Historic Receivables for Nektar Therapeutics (NKTR) over the last 13 years, with Sep 2025 value amounting to $200,000.

  • Nektar Therapeutics' Receivables was N/A to $200,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is 74.48% down from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Receivables is $200,000, which was down 83.28% from $1.2 million recorded in Q2 2024.
  • Nektar Therapeutics' 5-year Receivables high stood at $30.2 million for Q1 2022, and its period low was $200,000 during Q3 2025.
  • For the 3-year period, Nektar Therapeutics' Receivables averaged around $1.9 million, with its median value being $1.7 million (2023).
  • Per our database at Business Quant, Nektar Therapeutics' Receivables crashed by 90.09% in 2023 and then increased by 20.77% in 2024.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Receivables stood at $23.9 million in 2021, then slumped by 72.04% to $6.7 million in 2022, then plummeted by 74.48% to $1.7 million in 2023, then decreased by 10.41% to $1.2 million in 2024, then reached $200,000 in 2025.
  • Its last three reported values are $200,000 in Q3 2025, $1.2 million for Q2 2024, and $3.6 million during Q1 2024.